Literature DB >> 19224177

Clinical characteristics of paroxysmal kinesigenic choreoathetosis: diagnosis, treatment and prognosis.

Huicong Kang1, Qi Hu, Xiaoyan Liu, Feng Xu, Lin Chen, Suiqiang Zhu.   

Abstract

The clinical characters, diagnosis and differential diagnosis of paroxysmal kinesigenic choreoathetosis (PKC), and efficacy of the anti-epileptic drugs (AEDs) were investigated. Thirty-one patients with PKC were collected, and the clinical characters and change of EEG were analyzed. The average age of the first attack was 16.8 years old and the pinnacle was 10 to 20 years old. There were definite causes for every attack and the sudden movement was the most common one (92%). Time for the whole attack was always less than 1 min. The attack presented with muscle tension disturbance (83.9%), movement like dancing (16.1%), abnormal movement of mouth and face and other symptoms (16.2%). The attack tended to be very frequent and 71% patients were beyond once per day. The EEG examination and image scan of primary PKC were normal in most patients. Low dosage of AEDs could control the attack of 50%-77.3% patients. It was concluded that PKC was a common disease of movement disorder. The therapy by AEDs was very effective. PKC should be differentiated from epilepsy and the relationship between PKC and epilepsy needs further research.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19224177     DOI: 10.1007/s11596-009-0125-1

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  18 in total

1.  [Oxcarbazepine in the treatment of kinesigenic paroxysmal choreoathetosis].

Authors:  S Iglesias-Gómez; F J Vadillo-Olmo; J Abella-Corral; I Rodríguez-Constenla; M Peleteiro-Fernández; A Castro-García; M Noya-García
Journal:  Rev Neurol       Date:  2005 Sep 1-15       Impact factor: 0.870

2.  Gabapentin for familial paroxysmal dystonic choreoathetosis.

Authors:  R S Chudnow; R A Mimbela; D B Owen; E S Roach
Journal:  Neurology       Date:  1997-11       Impact factor: 9.910

Review 3.  Paroxysmal kinesigenic choreoathetosis: from first discovery in 1892 to genetic linkage with benign familial infantile convulsions.

Authors:  Nobumasa Kato; Miyuki Sadamatsu; Taeko Kikuchi; Norio Niikawa; Yukio Fukuyama
Journal:  Epilepsy Res       Date:  2006-08-09       Impact factor: 3.045

4.  New family with paroxysmal exercise-induced dystonia and epilepsy.

Authors:  Christoph Kamm; Petra Mayer; Manu Sharma; Gerhard Niemann; Thomas Gasser
Journal:  Mov Disord       Date:  2007-04-30       Impact factor: 10.338

Review 5.  Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: new diagnostic criteria.

Authors:  M K Bruno; M Hallett; K Gwinn-Hardy; B Sorensen; E Considine; S Tucker; D R Lynch; K D Mathews; K J Swoboda; J Harris; B W Soong; T Ashizawa; J Jankovic; D Renner; Y H Fu; L J Ptacek
Journal:  Neurology       Date:  2004-12-28       Impact factor: 9.910

6.  Paroxysmal kinesigenic dyskinesia and generalized seizures: clinical and genetic analysis in a Spanish pedigree.

Authors:  E Cuenca-Leon; B Cormand; T Thomson; A Macaya
Journal:  Neuropediatrics       Date:  2002-12       Impact factor: 1.947

7.  [Paroxysmal kinesigenic dyskinesia: a channelopathy? Study of 19 cases].

Authors:  G Fourcade; A Roubertie; D Doummar; M Vidailhet; P Labauge
Journal:  Rev Neurol (Paris)       Date:  2008-10-14       Impact factor: 2.607

8.  Topiramate therapy for paroxysmal kinesigenic choreoathetosis.

Authors:  Yuan-Gui Huang; Yun-Chun Chen; Fang Du; Rui Li; Ge-Lin Xu; Wen Jiang; Jing Huang
Journal:  Mov Disord       Date:  2005-01       Impact factor: 10.338

9.  [Ictal SPECT and paired stimulation SEP recovery curve in a patient with paroxysmal kinesigenic choreoathetosis].

Authors:  Dai Yamashiro; Masao Aihara; Chikako Ono; Hideaki Kanemura; Kazuo Hatakeyama; Hitoshi Shimoyama; Shinpei Nakazawa
Journal:  No To Hattatsu       Date:  2002-11

10.  Infantile convulsions and paroxysmal choreoathetosis in a consanguineous family.

Authors:  Ercan Demir; Jean François Prud'homme; Meral Topçu
Journal:  Pediatr Neurol       Date:  2004-05       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.